Toolkit/EV-ADSCs

EV-ADSCs

Construct Pattern·Research·Since 2026

Also known as: empty vector-transduced DBA/2J ADSCs

Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.

Summary

their effects on renal functional and structural indices were compared at week 15 with those of diabetic DBA/2J recipients of vehicle alone or of empty vector-transduced DBA/2J ADSCs (EV-ADSCs).

Usefulness & Problems

Why this is useful

This is the empty-vector-transduced autologous ADSC control used to benchmark the effect of adding allogeneic H-2Kb expression. It provides therapeutic comparison without the engineered allo-MHC feature.; control comparator for lentiviral-transduced autologous ADSC therapy in diabetic nephropathy

Source:

This is the empty-vector-transduced autologous ADSC control used to benchmark the effect of adding allogeneic H-2Kb expression. It provides therapeutic comparison without the engineered allo-MHC feature.

Source:

control comparator for lentiviral-transduced autologous ADSC therapy in diabetic nephropathy

Problem solved

It separates the effect of the engineered allo-antigen from the baseline effects of autologous ADSC treatment and vector handling.; controls for effects of autologous ADSC administration and vector transduction when comparing against H-2Kb-expressing ADSCs

Source:

It separates the effect of the engineered allo-antigen from the baseline effects of autologous ADSC treatment and vector handling.

Source:

controls for effects of autologous ADSC administration and vector transduction when comparing against H-2Kb-expressing ADSCs

Problem links

controls for effects of autologous ADSC administration and vector transduction when comparing against H-2Kb-expressing ADSCs

Literature

It separates the effect of the engineered allo-antigen from the baseline effects of autologous ADSC treatment and vector handling.

Source:

It separates the effect of the engineered allo-antigen from the baseline effects of autologous ADSC treatment and vector handling.

Published Workflows

Effects of Repeated Intravenous Injections of Autologous Adipose-Derived Mesenchymal Stromal Cells Expressing an Allogeneic MHC Protein in a Mouse Model of Diabetic Nephropathy.

2026

Objective: Engineer autologous adipose-derived mesenchymal stromal cells to express an allogeneic MHC-I protein and compare their therapeutic and immunological effects against autologous control ADSCs in a mouse model of diabetic nephropathy.

Why it works: The study rationale is that introducing a defined allogeneic MHC mismatch into otherwise autologous ADSCs can reveal how MSC-delivered allo-antigens alter anti-inflammatory and renal repair effects while also exposing adverse immune responses.

MSC-delivered allo-antigen presentationregulatory T cell enhancementreduced intra-renal myeloid infiltrationlentiviral transductionintravenous cell administrationcomparative in vivo efficacy assessment

Stages

  1. 1.
    Engineering of allo-MHC-expressing autologous ADSCs(library_build)

    This stage creates the engineered cell product needed to test how MSC-delivered allo-antigen affects therapeutic and immune outcomes.

    Selection: Generate DBA/2J ADSCs expressing the allogeneic class I MHC protein H-2Kb using lentiviral transduction.

  2. 2.
    Repeated intravenous treatment in diabetic mice(confirmatory_validation)

    This stage tests whether the engineered allo-MHC feature changes therapeutic performance in an established disease setting.

    Selection: Compare H-2Kb-ADSCs, EV-ADSCs, and vehicle after dosing at 11 and 13 weeks after diabetes initiation.

  3. 3.
    Immune and safety characterization(secondary_characterization)

    This stage determines whether improved renal outcomes are accompanied by beneficial immune regulation, harmful alloimmunity, or both.

    Selection: Assess immune modulation and adverse immunological consequences associated with H-2Kb-ADSC treatment.

Steps

  1. 1.
    Lentiviral transduction of DBA/2J ADSCs to express H-2Kbengineered cell product

    Create autologous ADSCs carrying a defined allogeneic MHC-I protein.

    The engineered cell product must exist before in vivo comparison of therapeutic and immune effects can be performed.

  2. 2.
    Repeated intravenous administration of engineered or control ADSCstherapeutic cell products

    Test therapeutic effects of H-2Kb-ADSCs against EV-ADSC and vehicle controls in established diabetic nephropathy.

    In vivo dosing follows cell engineering so the resulting products can be compared under the same disease timeline.

  3. 3.
    Week-15 comparison of renal functional and structural indicestested therapeutic cell products

    Measure whether engineered allo-MHC expression changes renal outcomes relative to autologous control ADSCs and vehicle.

    Outcome assessment is performed after repeated dosing to capture treatment effects in the established disease model.

  4. 4.
    Assess immune modulation and adverse immunological outcomesengineered therapeutic cell product under immune/safety evaluation

    Determine whether superior renal benefit is associated with Treg-linked immune modulation and whether alloimmune or organ-injury liabilities emerge.

    Immune and safety analysis follows efficacy readout to interpret mechanism and detect tradeoffs introduced by allo-MHC expression.

Taxonomy & Function

Primary hierarchy

Mechanism Branch

Architecture: A reusable architecture pattern for arranging parts into an engineered system.

Target processes

recombination

Implementation Constraints

cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: regulator

The abstract supports a need for DBA/2J ADSCs, empty-vector transduction, and intravenous dosing into diabetic DBA/2J mice. Comparable renal outcome measurements are required for evaluation.; requires empty vector transduction of DBA/2J adipose-derived MSCs; requires intravenous administration in the diabetic mouse model used here

It does not test allo-antigen-driven immune modulation. It also did not improve glycemia or survival in this study.; showed less reduction in BUN and uACR than H-2Kb-ADSCs; did not influence glycemia or survival in the reported comparison

Validation

Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication

Observations

mixedMouseapplication demomousemale DBA/2J mice with established diabetes

renal functional and structural comparison

Inferred from claim c2 during normalization. H-2Kb-ADSCs had superior beneficial effects on diabetic nephropathy severity compared with fully autologous EV-ADSCs. Derived from claim c2. Quoted text: However, H-2Kb-ADSCs recipients had greater reductions in BUN and uACR ... These novel findings demonstrated that ADSCs expressing an MHC-I allo-antigen had superior beneficial effects on DN than fully autologous ADSCs.

Source:

blood urea nitrogen(greater_reduction_than)urine albumin creatinine ratio(greater_reduction_than)
mixedMouseapplication demomousemale DBA/2J mice with diabetes

physiological outcome assessment

Inferred from claim c5 during normalization. Neither EV-ADSCs nor H-2Kb-ADSCs influenced glycemia or survival in the reported study. Derived from claim c5. Quoted text: Both EV-ADSCs and H-2Kb-ADSCs resulted in reduced ... compared to vehicle alone, without influencing glycemia or survival.

Source:

glycemia(no_change)survival(no_change)
successMousetherapeutic usemousemale DBA/2J mice with diabetes

renal functional and structural indices

Inferred from claim c1 during normalization. Both EV-ADSCs and H-2Kb-ADSCs reduced renal injury indices compared with vehicle alone in diabetic DBA/2J mice. Derived from claim c1. Quoted text: Both EV-ADSCs and H-2Kb-ADSCs resulted in reduced kidney/total body weight ratio, blood urea nitrogen (BUN), urine albumin creatinine ratio (uACR), mesangial matrix expansion (MME) and renal fibrosis compared to vehicle alone

Source:

blood urea nitrogen(reduced_vs)kidney/total body weight ratio(reduced_vs)mesangial matrix expansion(reduced_vs)renal fibrosis(reduced_vs)urine albumin creatinine ratio(reduced_vs)

Supporting Sources

Ranked Claims

Claim 1adverse immunological effectsupports2026Source 1needs review

H-2Kb-ADSC treatment also produced potentially detrimental immunological effects including alloantibodies and inflammatory liver injury.

Nonetheless, recipients of H-2Kb-ADSCs also had decreased splenic CD4/CD8 T cell ratios, increased circulating anti-H-2Kb IgG antibodies and histological and biochemical evidence of inflammatory liver injury.
circulating anti-H-2Kb IgG antibodies in H-2Kb-ADSC recipientsinflammatory liver injury histological and biochemical evidencesplenic CD4/CD8 T cell ratio in H-2Kb-ADSC recipients
Claim 2comparative superioritysupports2026Source 1needs review

H-2Kb-ADSCs had superior beneficial effects on diabetic nephropathy severity compared with fully autologous EV-ADSCs.

However, H-2Kb-ADSCs recipients had greater reductions in BUN and uACR ... These novel findings demonstrated that ADSCs expressing an MHC-I allo-antigen had superior beneficial effects on DN than fully autologous ADSCs.
blood urea nitrogen H-2Kb-ADSCs vs EV-ADSCsurine albumin creatinine ratio H-2Kb-ADSCs vs EV-ADSCs
Claim 3comparative therapeutic effectsupports2026Source 1needs review

Both EV-ADSCs and H-2Kb-ADSCs reduced renal injury indices compared with vehicle alone in diabetic DBA/2J mice.

Both EV-ADSCs and H-2Kb-ADSCs resulted in reduced kidney/total body weight ratio, blood urea nitrogen (BUN), urine albumin creatinine ratio (uACR), mesangial matrix expansion (MME) and renal fibrosis compared to vehicle alone
blood urea nitrogen reduced compared to vehicle alonekidney/total body weight ratio reduced compared to vehicle alonemesangial matrix expansion reduced compared to vehicle alonerenal fibrosis reduced compared to vehicle aloneurine albumin creatinine ratio reduced compared to vehicle alone
Claim 4immune modulation associationsupports2026Source 1needs review

Improved diabetic nephropathy severity with H-2Kb-ADSCs was associated with immune modulation including Treg enhancement and reduced intra-renal myeloid cell infiltration.

H-2Kb-ADSCs recipients had ... reduced intra-renal myeloid cell infiltration, increased splenic regulatory T cell (Treg) proportions and increased intra-renal Treg infiltration and FOXP3 and IL-10 mRNA.
FOXP3 mRNA in H-2Kb-ADSC recipientsIL-10 mRNA in H-2Kb-ADSC recipientsintra-renal myeloid cell infiltration in H-2Kb-ADSC recipientsintra-renal Treg infiltration in H-2Kb-ADSC recipientssplenic regulatory T cell proportions in H-2Kb-ADSC recipients
Claim 5no effectsupports2026Source 1needs review

Neither EV-ADSCs nor H-2Kb-ADSCs influenced glycemia or survival in the reported study.

Both EV-ADSCs and H-2Kb-ADSCs resulted in reduced ... compared to vehicle alone, without influencing glycemia or survival.
glycemia without influencing glycemiasurvival without influencing survival

Approval Evidence

1 source3 linked approval claimsfirst-pass slug ev-adscs
their effects on renal functional and structural indices were compared at week 15 with those of diabetic DBA/2J recipients of vehicle alone or of empty vector-transduced DBA/2J ADSCs (EV-ADSCs).

Source:

comparative superioritysupports

H-2Kb-ADSCs had superior beneficial effects on diabetic nephropathy severity compared with fully autologous EV-ADSCs.

However, H-2Kb-ADSCs recipients had greater reductions in BUN and uACR ... These novel findings demonstrated that ADSCs expressing an MHC-I allo-antigen had superior beneficial effects on DN than fully autologous ADSCs.

Source:

comparative therapeutic effectsupports

Both EV-ADSCs and H-2Kb-ADSCs reduced renal injury indices compared with vehicle alone in diabetic DBA/2J mice.

Both EV-ADSCs and H-2Kb-ADSCs resulted in reduced kidney/total body weight ratio, blood urea nitrogen (BUN), urine albumin creatinine ratio (uACR), mesangial matrix expansion (MME) and renal fibrosis compared to vehicle alone

Source:

no effectsupports

Neither EV-ADSCs nor H-2Kb-ADSCs influenced glycemia or survival in the reported study.

Both EV-ADSCs and H-2Kb-ADSCs resulted in reduced ... compared to vehicle alone, without influencing glycemia or survival.

Source:

Comparisons

Source-stated alternatives

The abstract contrasts EV-ADSCs with H-2Kb-ADSCs and vehicle alone.

Source:

The abstract contrasts EV-ADSCs with H-2Kb-ADSCs and vehicle alone.

Source-backed strengths

reduced kidney/total body weight ratio, BUN, uACR, mesangial matrix expansion, and renal fibrosis compared to vehicle alone

Source:

reduced kidney/total body weight ratio, BUN, uACR, mesangial matrix expansion, and renal fibrosis compared to vehicle alone

Compared with H-2Kb-ADSCs

The abstract contrasts EV-ADSCs with H-2Kb-ADSCs and vehicle alone.

Shared frame: source-stated alternative in extracted literature

Strengths here: reduced kidney/total body weight ratio, BUN, uACR, mesangial matrix expansion, and renal fibrosis compared to vehicle alone.

Relative tradeoffs: showed less reduction in BUN and uACR than H-2Kb-ADSCs; did not influence glycemia or survival in the reported comparison.

Source:

The abstract contrasts EV-ADSCs with H-2Kb-ADSCs and vehicle alone.

Ranked Citations

  1. 1.
    StructuralSource 1MED2026Claim 1Claim 2Claim 3

    Extracted from this source document.